Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

[1]  P. Therasse.  Immune-Related Response Criteria , 2020, Definitions.

[2]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[3]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[4]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[5]  A. Brenner,et al.  Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.

[6]  M. Beckmann,et al.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.

[7]  Joe Y. Chang,et al.  In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation , 2015, Molecular therapy. Nucleic acids.

[8]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[9]  Feng Ye,et al.  The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis , 2015, OncoTargets and therapy.

[10]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[11]  X. Chen,et al.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. , 2015, Cellular signalling.

[12]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Brown,et al.  Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer , 2014, Molecular Cancer Therapeutics.

[14]  G. Sen,et al.  dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[15]  K. Kelnar,et al.  In-Depth Analysis Shows Synergy between Erlotinib and miR-34a , 2014, PloS one.

[16]  K. Kelnar,et al.  Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates , 2014, Analytical chemistry.

[17]  A. Tolcher,et al.  A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[18]  Danli Xie,et al.  MicroRNA-34a Enhances T Cell Activation by Targeting Diacylglycerol Kinase ζ , 2013, PloS one.

[19]  Jane Zhao,et al.  TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  A. Lund,et al.  MicroRNA and cancer , 2012, Molecular oncology.

[21]  M. Negrini,et al.  Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.

[22]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[23]  A. Bader,et al.  Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo , 2012, Leukemia.

[24]  F. Slack,et al.  MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.

[25]  A. Bader,et al.  Developing therapeutic microRNAs for cancer , 2011, Gene Therapy.

[26]  Nam-Gyun Kim,et al.  p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling , 2011, Science Signaling.

[27]  H. Rehrauer,et al.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. , 2011, Blood.

[28]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  K. Kelnar,et al.  Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44 , 2010, Nature Medicine.

[30]  Anton J. Enright,et al.  SylArray: a web server for automated detection of miRNA effects from expression data , 2010, Bioinform..

[31]  D. Brown,et al.  The promise of microRNA replacement therapy. , 2010, Cancer research.

[32]  Ryan M. O’Connell,et al.  MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. , 2010, Immunity.

[33]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[34]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[35]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[36]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[37]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[38]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[39]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[40]  Anton J. Enright,et al.  Detecting microRNA binding and siRNA off-target effects from expression data , 2008, Nature Methods.

[41]  Min Zhang,et al.  Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres , 2008, BMC Cancer.

[42]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[43]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[44]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[45]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[46]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[47]  K. Kelnar,et al.  A qRT-PCR Method for Determining the Biodistribution Profile of a miR-34a Mimic. , 2015, Methods in molecular biology.

[48]  Jane Zhao,et al.  TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  S. Schinner.  Alterations in MicroRNA Expression Contribute to Fatty Acid–Induced Pancreatic β-Cell Dysfunction , 2009 .

[50]  G. Frija,et al.  Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. , 1993, Magnetic resonance imaging.

[51]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .